NL-OMON38778已完成不适用
A Single-Center, Phase I, Randomized, Double- Blind, Placebo-Controlled, First-In-Man Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Subcutaneous MSB0010841 (Anti-IL-17A/F Nanobody) in Healthy Male Subjects - MSB0010841 SAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Merck KGaA
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects,
- •18 - 45 yrs, inclusive,
- •20.0 - 30.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
1 期
oribogaine Therapy for Relief of Opioid withdrawal, Phase 1BSymptoms of opioid withdrawalMental Health - AddictionACTRN12613001064796DemeRx Inc27
进行中（未招募）
1 期
Clinical Trial to investigate the efficacy and safety of nintedanib/vargatef when combined with paclitaxel (chemotherapy) for treatment of patients suffering from metastatic melanoma with BRAF wildtypEUCTR2013-004458-34-DEniversity of Essen126
已完成
不适用
A Single-Center, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL-17A/F Nanobody) in Healthy Male SubjectsNL-OMON38479Merck KGaA32
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CH-4051 in healthy male subjects10003816rheumatoid arthritisNL-OMON32763Chelsea Therapeutics, Inc.56
已完成
不适用
A Phase I, Single-Centre, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARA 290 Administered Intravenously to Healthy Subjects, and extension in renal patientsNL-OMON33878Araim Pharmaceuticals, Inc20